Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
As of late 2025, the financial markets are in the midst of a profound transformation, driven by the dynamic and often divergent interplay between institutional behemoths and an increasingly empowered army of retail investors. This evolving landscape is characterized by heightened volatility, new thematic rallies, and a significant blurring of
The U.S. stock market is currently navigating a period of cautious optimism, working to regain solid ground after a tumultuous year marked by significant losses in early 2025 and persistent concerns about valuation. While major indices have shown remarkable resilience, underlying economic headwinds and the evolving landscape of artificial
A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?
The puzzle pieces are in place for the world's largest retailer by revenue to reach a milestone in 2026 that only a dozen public companies globally have achieved.
Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
The financial markets in late 2025 are signaling a significant, albeit cautious, shift away from the concentrated leadership that has defined much of the past two years. For an extended period, market gains were predominantly driven by a select cohort of mega-cap technology companies, often dubbed the "Magnificent Seven," largely
